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Macrophages as novel targets for erythropoietin
Abstract
BackgroundOur original demonstration of immunomodulatory effects of erythropoietin in multiple
myeloma, led us to the search of the cells in the immune system that are direct targets to erythropoietin.
The finding that lymphocytes do not express erythropoietin receptors, has led to the hypothesis that
other cells act as direct targets and thus mediate the erythropoietin effects. Having found erythropoietin
effects on dendritic cells thus led to the question of whether macrophages act as target cells to
erythropoietin. Design and Methods EPO effects on macrophages were investigated both in-vivo and
in-vitro. The in-vivo studies were performed on splenic macrophages and inflammatory peritoneal
macrophages, in recombinant human erythropoietin -treated, compared to untreated mice, as well as in
transgenic mice over-expressing human erythropoietin (tg6), compared to their control wild type
counterparts. The in-vitro effects of erythropoietin on macrophage surface markers and function were
investigated in murine bone marrow-derived macrophages treated with recombinant human
erythropoietin. Results Erythropoietin effects on macrophages were found under both the in-vivo and
in-vitro experiments. In-vivo treatment led to increased numbers of splenic macrophages, and of the
splenic macrophages expressing CD11b, CD80 and major histocompatibility complex class II. The
peritoneal inflammatory macrophages obtained from erythropoietin -treated mice displayed increased
expression of F4/80, CD11b, CD80 and major histocompatibility complex class II, and augmented
phagocytic activity. The macrophages derived in-vitro from bone marrow cells expressed erythropoietin
receptor transcripts, and in-vitro stimulation with erythropoietin activated multiple signaling pathways,
including signal transducer and activator of transcription (STAT)1 and 5, mitogen-activated protein
kinase, phosphatidylinositol 3-kinase and nuclear factor kappa B. Erythropoietin treatment in-vitro to
these cells up-regulated the cell surface expression of CD11b, F4/80 and CD80, it enhanced their
phagocytic activity and nitric oxide secretion, and also displayed augmented interleukin 12 secretion and
decreased interleukin 10 secretion in response to Lipopolysaccharide. ConclusionsOur results show that
macrophages are direct targets of erythropoietin and that erythropoietin treatment enhances their
pro-inflammatory activity and function. These findings point to a multifunctional role of erythropoietin
and its potential clinical applications as an immunomodulating agent.
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ABSTRACT 
Background 
We had earlier described the immunomodulatory effects of erythropoietin (EPO) in multiple 
myeloma. We reported that dendritic cells express EPO receptors (EPO-Rs), and that EPO 
stimulation enhances their survival and function. We now focus on macrophages as additional 
EPO targets.  
Design and Methods 
The in-vivo effects of EPO on macrophages were assessed by analysis of splenic macrophages 
and inflammatory peritoneal macrophages in recombinant human EPO (rHuEPO)-treated mice 
and in human EPO-over-expressing transgenic tg6 mice. The results were compared to control 
counterparts. The in-vitro effects of EPO were investigated in a model of murine bone marrow-
derived macrophages (BMDMs) treated with rHuEPO.  
Results 
EPO in-vivo treatment increased the number of splenic macrophages and of the splenic 
macrophages expressing CD11b, CD80 and MHC class II. The peritoneal inflammatory 
macrophages obtained from EPO-treated mice displayed increased expression of F4/80, CD11b, 
CD80 and MHC class II, and augmented phagocytic activity. These results were supported by 
the  in-vitro finding that BMDMs express EPO-R mRNA. In-vitro stimulation of BMDMs with 
rHuEPO activated multiple signaling pathways, including STAT1, STAT5, MAPK, AKT and 
NFB. EPO treatment of BMDMs up-regulated their surface expression of CD11b, F4/80 and 
CD80, and enhanced their phagocytic activity and nitric oxide secretion. EPO treatment of 
lipopolysaccharide-stimulated BMDMs augmented IL-12 secretion and decreased IL-10 
secretion.  
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Conclusions 
Our results showed that macrophages are direct targets of EPO and that EPO treatment enhances 
their pro-inflammatory activity and function. These findings point to a multifunctional role of 
EPO and its potential clinical applications as an anti-neoplastic immunomodulator. 
 
Key words: EPO-R, pro-inflammation, macrophages, STAT 
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Introduction 
Erythropoietin (EPO), the erythropoietic hormone, is the main treatment option for several types 
of anemia, including those related to cancer. The function of EPO is regulated by activation of its 
receptor (EPO-R) on erythroid progenitors, thereby promoting the anti-apoptotic and survival 
signaling pathways. Recent studies have demonstrated that the functions of EPO are not limited 
to erythroid cells, and that EPO displays non-erythroid effects that are also related to anti-
apoptotic processes, such as in heart failure improvement and neuroprotection (1). Ongoing 
studies in our laboratory have demonstrated anti-neoplastic, immunomodulatory functions of 
EPO that were primarily observed in multiple myeloma (MM) patients receiving recombinant 
human EPO (rHuEPO) treatment for their anemia. This phenomenon was revealed unexpectedly 
when rHuEPO treatment to these patients not only elevated their hemoglobin (Hb) levels, but 
also prolonged their survival rates and quality of life (2). Further studies showed that treatment 
of MM patients with rHuEPO was actually associated with a marked improvement of various 
immunological parameters and functions (3). Analysis of murine MM models reinforced these 
data and pointed to anti-neoplastic activities of EPO, mediated by improved CD8 lymphocyte 
functions (4, 5). In parallel, when assessing the humoral compartment of the immune system, we 
found that EPO treatment resulted in increased immunoglobulin production in antigen-injected 
mice, and enhanced lipopolysaccharide (LPS)-mediated splenocyte proliferation (6).   
 Since EPO-Rs were not detectable in lymphocytes (3), we considered the possibility that 
other cells that do express the receptor may act as mediators of EPO function. Our search for 
possible mechanisms of EPO immunomodulatory effects led us to the novel discovery that 
dendritic cells (DCs) express the EPO-R, and that stimulation with EPO enhances their survival 
and function (7, 8). Studies in murine models showed that EPO increased the splenic DC 
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population with a higher cell surface expression of the costimulatory molecules CD80 and CD86 
(8). Further analysis carried out on bone marrow-derived DCs  led to the findings that in addition 
to EPO-R mRNA expression, in-vitro stimulation with EPO enhanced their viability, upregulated 
CD80, CD86 and MHC class II expression, augmented the secretion of interleukin (IL)-12 and 
activated multiple signaling pathways (8). 
 Based on these findings, we hypothesized that macrophages are also potential targets of 
EPO. This would be an important discovery, since macrophages and DCs have common 
progenitors (9), and macrophages are also powerful antigen-presenting cells and serve as key 
effectors of the innate immune response (10, 11). The current study was designed to determine 
whether macrophages express EPO-Rs and whether they are affected directly by EPO. We 
focused on examining the effects of EPO on macrophage phenotype and functions, under both 
in-vivo and in-vitro experimental conditions.   
 
Design and Methods 
Mice 
 Female mice of the inbred C57BL strain, aged 8-12 weeks, were obtained from the Tel-
Aviv University Animal Breeding Center. They were used to generate bone marrow- derived 
macrophages (BMDM) and for the EPO-injected mouse model. The transgenic mice over-
expressing HuEPO (tg6) have been previously described (6, 12). Female tg6 mice and their wild 
type (wt) littermates, aged 3–5 months, were used for experiments with this murine model. 
Mouse handling and the experimental procedures were approved by the Institutional Animal 
Care and Use Committee of the Tel-Aviv University (number M-07-068). 
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Reagents 
 GMP-manufactured sterile syringes of rHuEPO (Eprex®) as used for patient care were 
kindly provided by Janssen Cilag, Israel, and employed throughout this study, thus ensuring the 
critically assured absence of toxins in the rHuEPO preparation. LPS from the E. coli strain 
0127:B8 (Sigma) was reconstituted in sterile double distilled water (DDW) at 1 mg/ml stock 
solution and kept at -20°C. Anti human EPO Ab - MAB287 (R&D systems, USA) was 
reconstituted in phosphate buffered solution (PBS) at 1 mg/ml solution and kept at -20°C. 
 
Preparation of murine splenocytes 
 The mice were sacrificed by cervical dislocation and their spleens were immersed and 
forced through 200-m pore-size wire mesh using the plunger from a 5 ml syringe to produce a 
single cell suspension. The cells were sedimented by centrifugation, and erythrocytes were lysed 
by hypotonic shock (10 s in sterile DDW), followed by the addition of 0.1 volume of ×10 HBSS. 
Splenocytes were then prepared for flow cytometry analysis. 
 
Isolation of macrophages from the peritoneal exudate 
 To induce nonspecific inflammatory exudates, mice were injected intraperitoneally (i.p.) 
with 1 ml of 3% thioglycollate (Sigma, Israel). These mice were sacrificed 3 days later and all 
the peritoneal exudate cells were obtained by injecting 10 ml of ice-cold PBS into the peritoneal 
cavity. After a gentle massage, the fluid was harvested and the cells were centrifuged and 
washed before further use. 
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Generation of bone marrow-derived macrophages 
 Preparation of BM cell cultures was based on the protocol described by Boltz-Nitulescu 
et al. (13). Briefly, BM cells were isolated from femurs and tibias of the experimental mice. The 
cells were then incubated for 7 days in DMEM culture medium supplemented with 30% L-
conditioning medium that was replenished on the 4th day. The non-adherent cells were purged 
and the macrophages (adherent cells) were collected by treatment with 15.5 mM EDTA in PBS 
for 10 min. The population of macrophages (BMDMs), as assessed by expression of CD11b 
surface molecule, was typically 99% pure. The BMDMs were washed, and cultured for 24 h in 
DMEM and collected by 15 mM EDTA treatment. For flow cytometry analysis and 
phagocytosis, the BMDMs were cultured in the presence or absence of rHuEPO. For cytokine 
detection, 0.05 g/ml LPS was added to the cultures in the presence or absence of rHuEPO.  
 
Flow cytometry analysis 
 The following fluorescence-conjugated antibodies were used: PE CD11b (Miltenyi 
Biotech Inc.), FITC F4/80, PE MHC class II (I-A/I-E), PE-Cy5 CD80 (eBioscience) and the 
relevant isotype controls. BMDMs or splenocytes were incubated with the antibodies for 30 min 
at 4oC and washed with PBS. The cells were then analyzed on a FACSort flow cytometer 
(Becton-Dickinson). Ten thousand total events were collected and gated for analysis on live cells 
as determined by forward and side scatter. The results were analyzed using WinMDI software. 
 
Phagocytosis of fluorescently labeled E. coli by macrophages  
 Peritoneal inflammatory macrophages or BMDMs were seeded in 6-well plates (1 × 106 
cells per well) for 2 h at 37°C to allow cell adhesion. E. coli was heat-killed by incubation at 
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65°C for 1 h and labeled with FITC (Sigma), 0.2 mg per ml in 0.1 M NaHCO3 (pH 9.0) for 1 h at 
37 °C. FITC-labeled E. coli (10 × 107 CFU) were added to the cells (10 bacteria per 
macrophage). After incubation for 1 h at 37°C or at 4°C (to determine fluorescence background), 
phagocytosis was stopped by immediate transfer of the cells to 4°C and washing with ice-cold 
PBS. The cells were treated with 0.1% crystal violet to quench extracellular fluorescence, and 
then fixed with 2% paraformaldehyde. They were collected by scraping with a rubber policeman 
and analyzed using a FACSort flow cytometer (Becton-Dickinson). The results are represented 
as a phagocytosis index, defined as the percent of cells with internalized E. coli minus the 
background fluorescence, multiplied by the mean fluorescence intensity. 
 
Reverse transcription and polymerase chain reaction analysis 
 All the procedures were performed according to the manufacturer’s instructions. Total 
RNA was isolated from 7-day cultures of pure untreated BMDMs using the TRIzol reagent 
(Invitrogen). Reverse transcription was performed using MMLV Reverse Transcriptase 
(Promega) from 1-2 µg of total RNA. Following cDNA synthesis, PCR was performed using 
Taq polymerase (Biolabs) for EPO-R or  actin transcripts, using oligonucleotide primers 
derived from the murine EPO-R (forward and reverse primers derived from EPO-R exons 1 and 
2, respectively) and  actin sequences: EPO-R forward -5’ ATGGACAAACTCAGGGTGC 3’, 
reverse – 5’ CTAGGAGCAGGCCACATA 3’; actin forward -  5’ 
TTCTTTGCAGCTCCTTCGTTGCCG 3’, reverse – 5’ TGGATGGCTACGTACATGGC 
TGGG 3’. 
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Bone marrow-derived macrophages for biochemical analysis 
 The cells were starved for 1 h at 37oC by incubating them in DMEM medium without any 
supplements, after which 50 U/ml rHuEPO was added to the cells at different time points, as 
specified. In order to neutralize EPO activity with anti human EPO Ab, 50 U/ml rHuEPO 
rHuEPO and 10 g/ml of the Ab were incubated for 1 h at 37oC, prior to their addition to the 
cells. Phosphatase inhibitors (2 mM ZnCl2, 2 mM Vanadate, 50 mM NaF, and 20 mM Na4P2O7) 
were then added on ice, and the cells were scraped off and collected. The cells were centrifuged 
at 14,000 rpm and extracted as described below.  
 Cytoplasmic and nuclear cell extracts were prepared as followed.  The cell pellets were 
resuspended in buffer A - 0.1 mM EDTA, 10 mM KCl, and 10 mM HEPES (pH 7.9), to which a 
protease inhibitor cocktail (CompleteTM protease inhibitors; Roche Diagnostics) was freshly 
added, and incubated on ice for 10 min. The cells were lysed by adding 0.75% Nonidet P-40, and 
the lysate was then kept on ice for 5 min with repeated vortexing. The lysate was centrifuged at 
5,000 rpm for 5 min to pellet the nuclei, and the supernatant (cytoplasmic extract) was stored at –
80°C. The nuclear pellets were first washed in cold PBS and then resuspended in buffer C 
consisting of 1 mM EDTA, 0.4 M NaCl, and 20 mM HEPES (pH 7.9), with fresh addition of a 
protease inhibitor cocktail as mentioned above, and incubated for 15 min on ice with repeated 
vortexing. The suspensions were clarified by centrifugation at 14,000 rpm for 10 min. The 
supernatants were recovered as nuclear extracts and stored at −80 °C.  
Whole cell extracts were prepared as described elsewhere (14). The cells were lysed at 4oC in 
lysis buffer (50 mM Tris pH 7.4, 1% Triton X-100, 5 mM iodoacetamide, 5 mM EDTA, and 150 
mM NaCl) containing phosphatase and protease inhibitors. Lysates were spun at 14,000 rpm for 
10 min and supernatants were recovered and stored at −80°C. 
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Immunoblotting 
All supernatants were separated on 10% SDS-PAGE and transferred onto a nitrocellulose 
membrane filter. The nitrocellulose membrane was incubated with the following antibodies: 
phosphoERK1/2 [Sigma Chemicals]; phosphoSTAT5 (Tyr694), STAT5, phosphoSTAT3 
(Tyr705), STAT3, phosphoSTAT1, STAT1, phosphoAKT (Ser473), AKT [Cell Signaling]; 
ERK2, histone H1 (AE-4) [Santa Cruz], actin [Chemicon], and p65 (Rel A) Ab-1 [Labvision] 
followed by labeled polymer HRP anti-rabbit or anti-mouse antibodies [Dako]. 
 
Cytokine detection 
 Supernatants from BMDM cultures were collected after 24 h of incubation with LPS in 
the presence or absence of rHuEPO, and then analyzed for IL-12 p70 (IL-12) and IL-10. 
Cytokine levels were determined by ELISA kits (Peprotech) according to the manufacturer’s 
instructions.   
 
Nitric oxide secretion  
 Supernatants from BMDM were harvested after 24 h of culture, and levels of NO were 
measured as the nitrite concentration by mixing equal volumes of culture supernatants (40 µl) 
and Griess reagent (Sigma). Nitrite concentrations were determined by comparing the 
absorbance values (at 540 nm) of the test samples with a standard curve generated by serial 
dilutions of 100 µM sodium nitrite. 
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Statistical analysis 
 Comparisons between data of the control treatment versus data from EPO treatment were 
performed using Student's t-test. p values less than 0.05 were considered to indicate statistical 
significance. 
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Results 
 Since macrophages are a highly heterogeneous population, with multiple functions and 
diverse phenotypes (15), we chose to explore the effects of EPO on macrophages that are steady-
state residents in the spleen and can be easily identified, as well as macrophages induced by 
thioglycollate in the peritoneum and those generated in vitro from bone marrow progenitors  The 
in-vivo effects of EPO were examined under two experimental models. The first model consisted 
of rHuEPO-injected mice, with diluent-injected mice serving as controls. The second model 
consisted of the tg6 transgenic mice over-expressing human EPO (6, 12), with their wt 
littermates serving as controls. Mice spleens were harvested and phenotyped by flow cytometry 
analysis.  
 
In-vivo effects of erythropoietin on splenic macrophages 
 Splenic macrophages were identified by expression of the pan macrophage marker F4/80, 
which is associated with macrophage differentiation (9, 16). Further analysis of the F4/80-
positive cells was performed to assess the expression of CD11b, a marker of macrophage 
activation, and MHC class II and CD80, markers of antigen presentation (11, 17). The proportion 
of cells expressing the F4/80 cell surface marker indicated that both the rHuEPO-injected mice 
and, to a larger extent, the tg6 mice, exhibited a significant increase in the splenic macrophage 
population compared to their respective control groups (Figure 1A+B). Moreover, we found 
increased proportions of splenic macrophages (F4/80+ cells) expressing both CD80 and MHC 
class II markers (Figure 1C) in the rHuEPO-injected and the tg6 mice. However, a significant 
increase in the number of splenic macrophages expressing CD11b was observed only in the tg6 
mice (Figure 1C), suggesting that EPO affects this population in a dose-dependent manner. Of 
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note, we did not detect any difference in the expression of CD68 macrophage activation 
molecule in relation to the excessive availability of EPO compared to the relevant controls (data 
not shown). These results suggest an effect of EPO on macrophage differentiation, as reflected 
from the increase in the F4/80+ cell population. Furthermore, EPO was found to influence the 
macrophage phenotype towards a pro-inflammatory cell type, as demonstrated by the 
enhancement of CD11b, CD80 and MHC class II populations.  
 
In-vivo effects of erythropoietin on the peritoneal inflammatory macrophages 
 In order to determine whether EPO can affect the function of inflammatory macrophages, 
we assessed activated peritoneal macrophages induced by thioglycollate administration to the 
peritoneum in both rHuEPO-injected and tg6 mice. The peritoneal macrophages were identified 
by CD11b expression. The cell surface expression of CD11b, F4/80, MHC class II and CD80 
molecules increased significantly in both the rHuEPO-injected and tg6 mice compared to their 
control counterparts (Figure 2A+B), indicating that excessive availability of EPO led to an 
enhanced activation status of the macrophages. We then investigated the phagocytic ability of the 
macrophages using the functional assay of uptake of E. coli bacteria. Both experimental models 
showed enhanced macrophage phagocytic activity of E. coli bacteria (Figure 2C). It would 
therefore appear that EPO may lead to improved activation and function of the peritoneal 
inflammatory macrophages. Taken together, excessive availability of EPO resulted in 
enhancement of the pro-inflammatory phenotype and function of both splenic steady-state and 
inflammatory-induced peritoneal macrophages. The results of these in-vivo models thus showed 
that macrophages are, indeed, influenced by EPO. 
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In vitro studies on bone marrow–derived macrophages 
Erythropoietin receptor expression and activation in bone-marrow–derived macrophages 
 We then investigated macrophages derived in-vitro from the mouse bone marrow cultures 
in order to determine if EPO can affect macrophages directly. We first investigated whether 
BMDM expressed the EPO-R, and subsequent RT-PCR analysis demonstrated that EPO-R 
mRNA is indeed expressed in these cells (Figure 3A). We further investigated EPO-R-associated 
signaling in the BMDMs. Activation of the signal transducer and activator of transcription 
(STAT) pathways, specifically STAT5, comprise an essential step in the EPO-R signaling 
cascade (18). Therefore, we tested whether EPO treatment has any effect on phosphorylation of 
the STATs. BMDMs were treated in-vitro with rHuEPO and subjected to immunoblot analysis. 
Following in-vitro EPO treatment, we detected STAT5, STAT3 and STAT1 phosphorylation in 
the BMDMs (Figure 3B). Thus, involvement of the STAT pathways, specifically STAT5, 
implies that EPO-R is activated following EPO treatment.   
 We then examined whether EPO treatment in-vitro can also trigger signaling pathways 
that are known to participate in macrophage activation, including MAPK, PI3K and NFkB (19). 
As displayed in Figure 3C, in-vitro EPO treatment to BMDMs resulted in phosphorylation of 
ERK2 and AKT and translocation of p65 to the nucleus. The inhibition of EPO-,mediated 
STAT5 activation by the anti human EPO Ab, ensure EPO specificity of the above mentioned 
signaling pathways (Figure 3D). It should be noted that the background stimulation in the 
presence of antibody alone could derive from FC-mediated activation of the BMDMs which 
harbor an Fc receptor. The specificity of the antibody towards EPO, was verified by the lack of 
effect on GMCSF mediated activation of STAT5 (data not shown). 
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We could therefore conclude that exposure of BMDM to EPO results in activation of the MAPK, 
PI3K and NFkB signaling pathways.   
 
Erythropoietin effects on the bone-marrow–derived macrophage phenotype and function 
 We examined whether EPO treatment in-vitro can affect BMDM function. BMDMs were 
cultured in-vitro with or without rHuEPO for 24 h. E. coli phagocytosis and NO secretion assays 
were performed in order to assess the innate functions of the BMDMs. Macrophage activation 
was assessed by phenotype analysis based on CD11b, F4/80 and CD80 expression. The BMDMs 
treated with EPO displayed enhanced phagocytosis and NO secretion (Figure 4). In addition, 
EPO treatment of the BMDMs resulted in up-regulated cell surface expression of CD11b, F4/80 
and CD80 (Figure 5). These results reinforce the findings on the in-vivo effects of EPO, in which 
excessive availability of EPO led to similar effects on macrophage phenotype and activity. 
However, the in vitro experiments on BMDM failed to disclose any effect on MHC class II 
expression, which had been up-regulated under the in-vivo experimental conditions (data not 
shown).  
 We next determined the cytokine secretion profile of macrophages as an indication of 
function by analyzing the BMDM secretions of IL-12 and IL-10 that represent opposing 
immunological functions. Specifically, IL-12 is a pro-inflammatory cytokine related to the 
development of TH1 type response, whereas IL-10 has anti-inflammatory activities and may lead 
to a TH2 type response  (17, 19). Cytokine secretion by BMDMs was performed on cultures 
treated with LPS in the presence or absence of rHuEPO. EPO treatment of the LPS-stimulated 
BMDMs resulted in increased IL-12 secretion and reduced IL-10 secretion (Figure 6).   
L. Lifshitz et al.    Macrophages as novel target cells for erythropoietin 
 
16 
 
 Taken together, our in-vitro results showed that macrophages are indeed direct targets of 
EPO immunomodulatory effects. These effects, which stem from the interaction between EPO 
and macrophages, indicate that EPO enhances the activation and function of macrophages 
towards a pro-inflammatory response.   
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Discussion 
 We had hypothesized that macrophages are potential targets of EPO. The results of the 
present study supported our hypothesis by showing that macrophages are affected by EPO and 
that they are direct target cells of EPO. Moreover, we demonstrated that EPO treatment enhances 
the pro-inflammatory phenotype and function of different macrophage populations, including 
steady-state splenic resident macrophages, as well as thioglycollate-induced peritoneal 
macrophages and the in vitro established BMDM. The intention to focus on the 
immunomodulatory functions of EPO arose from our previous studies in which we showed that 
EPO treatment of MM patients as well as MM murine models was associated with improved 
immunological functions (2-6). Those studies in combination with observations in nonmalignant 
models (6) of the immune system provided evidence of EPO’s effect on both the cellular and the 
humoral compartments of the immune system. Specifically, EPO treatment was associated with 
enhanced lymphocyte activity of both T and B cells (3, 4, 6). However, EPO-R expression or 
direct EPO stimulation on lymphocytes could not be demonstrated to date.  
 Macrophages and DCs both develop from common progenitors and share similar surface 
markers (20, 21). Together with their many functions relating to the innate immune response, 
macrophages also display antigen presentation activities, although they are less potent than DCs 
(17), which have also been viewed as a subtype of macrophages (22).  
 Previous studies have described the effects of EPO on certain macrophage populations. 
The tg6 mice have been reported to have increased populations of liver and duodenal mucosa 
macrophages (23, 24), and the liver macrophages in tg6 mice also displayed enhanced 
erythrophagocytic activity (24). Expression of EPO-R was shown in wound-healing 
macrophages, and EPO enhanced the activity of these macrophages (25). We employed a variety 
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of experimental models that had excessive availability of EPO in the search of possible effects of 
EPO on macrophages. These models included in-vivo administration of EPO, transgenic mice 
over-expressing rHuEPO, as well as direct in vitro exposure of macrophages to EPO. The EPO-
driven increase in the splenic macrophage levels (CD11b, CD80 and MHC class II expression) 
could result from enhanced proliferation of macrophage progenitors or the prolonged viability of 
the existing macrophages. We observed similar effects of EPO on the splenic DC population in 
previous studies (8), suggesting that the activities of EPO could be related to an effect on the 
common DC and macrophage progenitors. Notably, EPO effects on both macrophages and DCs 
were more profound in the tg6 mice, probably due to the continuous exposure to high EPO 
levels. 
 The effect of EPO on macrophages was also evident in the peritoneal inflammatory 
macrophages. Here, EPO treatment enhanced macrophage activation as expressed by the 
augmented expression of CD11b, F4/80, CD80 and MHC class II and the improved phagocytic 
function. Notably, unlike the splenic macrophages, EPO treatment was not associated with an 
increase of the total number of the peritoneal macrophages (data not shown). As such, these 
findings suggest that EPO modulates peritoneal macrophage activity, but not migration of the 
macrophages towards the inflamed peritoneum. 
 The in-vitro administration of EPO enabled us to determine whether EPO can directly 
affect the macrophages, as well as to assess EPO-driven cellular events. BMDMs were chosen 
for the in-vitro studies based on the RT-PCR analysis that showed mRNA expression of EPO-R. 
The RT-PCR method was selected for this analysis due to the low levels of endogenous cellular 
EPO-R (26) and the fact that the anti-murine EPO-R antibodies that we routinely use in our 
studies (14) could not detect the EPO-R protein (data not shown).  
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 The functionality of the BMDM EPO-R was inferred by the EPO-mediated activation of 
the STAT5, STAT3 and STAT1 pathways in these cells. The STAT5 pathway is considered to 
be the central signaling pathway activated by the EPO-R and crucial for erythropoiesis (18). The 
role of STAT1 in erythropoiesis is less clear (27), although it does play an essential role in 
macrophage pro-inflammatory activation (1). Interestingly, we detected EPO-driven STAT3 
activation but not STAT1 or STAT5 in DCs (8). STAT3, similar to STAT1, is not essential for 
erythropoiesis (27), but it still plays a role in DC development (28). Thus, we assume that EPO-
mediated activation of the different STAT subtypes is determined by the cell type and/or 
environment, enabling STAT3 activation in DCs and STAT1 STAT3 and STAT 5 activation in 
macrophages.  
 Following EPO treatment, the BMDMs also exhibited activation of the PI3K, MAPK and 
NFkB pathways. The activation of these pathways is pivotal in macrophage inflammatory 
function, including cytokine secretion and phagocytosis (29, 30). These pathways are also 
essential in the EPO-R activation of both erythroid (18) and non-erythroid cells (31, 32). 
Notably, EPO treatment that activated signaling pathways did not enhance macrophage survival 
or proliferation (data not shown).  
In-vitro EPO-mediated activation of the BMDMs led to a pro-inflammatory phenotype and 
function of the cells. This was evident through increased expression of F4/80, CD11b and CD80, 
elevated phagocytosis and increased NO secretion following EPO treatment. Furthermore, the 
EPO-dependent elevated IL-12 and decreased IL-10 secretion suggest that EPO treatment not 
only enhances the pro-inflammatory status of the macrophages, but that it can also shift the 
macrophages typing to M1. Importantly, M1 macrophages are considered as being effector cells 
that enhance the TH1 response, and they can enable anti-neoplastic activity (17). Thus, it is 
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possible that the anti-neoplastic activity of EPO, as previously seen in MM patients (4) as well as 
in murine experimental models (5), is also regulated by macrophages shifting to an M1 type 
following EPO activation.  
 The current study reinforces our earlier ones on DCs and macrophages and on MM in 
emphasizing the role of EPO as an immunomodulator. This is especially relevant in light of the 
ongoing safety concerns regarding EPO treatment. Although EPO-R expression has been 
reported in various types of solid tumors (31), their functionality remains controversial (33, 34).  
 In conclusion, we demonstrated that EPO can directly affect macrophages, leading to a 
pro-inflammatory activity and function. We propose that the immunomodulatory activities of 
EPO are mediated, at least in part, by macrophages and DCs.  
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Figure 1. In-vivo effects of erythropoietin (EPO) manifested in splenic macrophages. Flow 
cytometry analysis of splenocytes from C57BL/6 mice injected three times (every other day 
during one week) with 180 U rHuEPO (EPO) or with the diluent (DILU) as a negative control, 
and from tg6 and their wild type (wt) littermates. (A) Density plots for F4/80 and MHC class II 
expression. (B) Summary of the number of splenic macrophages: F4/80+ splenocytes. (C) 
Summary of the number of macrophages: F4/80+ splenocytes also expressing CD11b and 
CD80/MHC class II. The graph and table represent the mean ±S.E.M of three independent 
experiments, each depicting three female mice per experimental group, *p<0.05, **p<0.01 for 
EPO/tg6 vs. diluent/wt, respectively. 
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Figure 2. In-vivo effects of erythropoietin (EPO) on inflammatory macrophages. Flow 
cytometry analysis of thioglycollate-induced peritoneal macrophages from C57BL/6 mice 
injected three times (every other day during one week) with 180 U rHuEPO (EPO) or with 
diluent (DILU) as a negative control, and from tg6 and their wild-type (wt) littermates. (A + B) 
peritoneal macrophages (identified by CD11b expression) were analyzed for CD11b, F4/80, 
CD80 and MHC class II cell surface expression. Surface expression of these molecules is 
represented as black or gray histograms. Isotype controls (Iso) are represented by broken line 
histograms. Histograms represent one of at least three independent experiments, displaying 
similar results. (A) rHuEPO-injected mice and diluent injected mice indicated by black and gray 
histograms, respectively. (B) The tg6 and their wt littermates indicated by black and gray 
histograms, respectively. (C) Analysis of thioglycollate-induced peritoneal macrophages 
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incubated with FITC-labeled E. coli bacteria. Phagocytosis index = (% of FITC-positive cells) × 
(mean fluorescence intensity). *p<0.05 for EPO/tg6 vs. diluent/wt, respectively. The figure 
represents a total of three experiments.  
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Figure 3. Erythropoietin receptor (EPO-R) expression and activation in bone marrow-
derived macrophages (BMDMs). (A) EPO-R expression in BMDMs. EPO-R mRNA from 
murine BMDMs (99% purity) was reverse-transcribed and subjected to PCR analysis for murine 
EPO-R and actin transcripts using oligonucleotide primers, thus yielding 300 and 457 bp 
fragments, respectively. Lane 1: RNA of BMDMs. Lane 2: Positive control. cDNA of BaF/3 
cells transfected with murine EPO-R (14). Lane 3: cDNA of BMDMs. Lane 4: Negative control. 
cDNA of MBA cells (35). (B - C) Stimulation of BMDMs with EPO activates multiple signaling 
pathways. BMDMs were treated in-vitro with 50 U/ml of recombinant human EPO (rHuEPO) 
for the indicated time periods. (B) Cell lysates of the cytosolic fraction were subjected to 
immunoblot analysis with the indicated antibodies. STAT5, STAT1 and STAT3 signaling were 
determined by phosphorylation. Total STAT levels are depicted for normalization. (C) Cell 
lysates of the cytosolic (ERK and AKT immunoblots) and nuclear fractions (p65 immunoblot) 
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were subjected to immunoblot analysis with the indicated antibodies. MAPK and PI3K signaling 
were determined by ERK1/2 and AKT phosphorylation, respectively. Total ERK2 and AKT 
levels are depicted for normalization. NF-κB signaling was detected by nuclear p65 
internalization. Nuclear histone is depicted for normalization. All micrographs represent one of 
at least three similar independent experiments. (D) Neutralization of EPO mediated signaling by 
anti human EPO Ab. BMDMs were treated in-vitro for 10 min with 50 U/ml of rHuEPO in the 
presence or absence 10g/ml of anti human EPO Ab, or with antibody alone. Cell lysates of the 
cytosolic fraction were subjected to immunoblot analysis with the indicated antibodies. pSTAT5 
and total STAT5 levels are depicted, NT - non treated; Ab - anti human EPO Ab. 
Immunoblots represent one of at least three independent experiments, displaying similar results. 
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Figure 4. Erythropoietin (EPO) in-vitro leads to enhanced bone marrow-derived 
macrophage (BMDM) phenotype innate functions. BMDMs were cultured in-vitro with 5 
U/ml rHuEPO for 24 h with EPO (EPO) or without EPO (control). (A) Cells were washed and 
incubated with FITC labeled E. coli bacteria, and then subjected to FACS analysis. Phagocytosis 
index = (% of FITC positive cells) × (mean fluorescence intensity). (B) Supernatants were 
collected and nitric oxide (NO) secretion was detected using Griess reagent. Graphs represent the 
mean ± S.E.M of three independent experiments. *p<0.05, **p<0.01 for EPO vs. control.  
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Figure 5. Erythropoietin (EPO) in-vitro affects the marrow-derived macrophage (BMDM) 
phenotype. BMDMs were cultured in-vitro with (EPO) or without (control) 5 U/ml recombinant 
human EPO (rHuEPO) for 24 h. Flow cytometry analysis of BMDMs of CD11b, F4/80 and 
CD80. Surface expression of these molecules is represented as black (EPO treated) or gray 
(control) histograms. Isotype controls (Iso) are represented by broken line histograms. Graphs 
represent the mean percentage of mean fluorescence intensity (MFI) increase of EPO-treated 
cells vs. control cells. *p<0.05 for EPO vs. control. 
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Figure 6. Erythropoietin (EPO) in-vitro leads to increased secretion of IL-12 and decreased 
IL-10 secretion by marrow-derived macrophages (BMDMs). BMDMs were cultured in-vitro 
with 0.05 g/ml lipopolysaccharide (LPS) in the presence or absence of recombinant human 
EPO (rHuEPO) for 24 h. Cell culture supernatants were analyzed for the levels of IL-12 and IL-
10, by ELISA. Graphs represent the mean cytokine concentration ± S.E.M. of at least three 
independent experiments. *p<0.05, **p<0.01 for EPO-treated cells vs. non-EPO-treated cells. 
